Drug Trial Radar · NCT06087796
Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 2023
Primary completion
Sep 2024
Study completion Oct 2024
Sponsor
- Lead sponsor
- Assiut UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of topical pentoxifylline 2% gel and topical metformin 10% gel versus topical betamethasone valerate 0.1% cream, in treatment of patchy alopecia areata.
Conditions
- Alopecia Areata
Interventions
Betamethasone Valerate 0.1% CreamDrug
Topical treatment modality for alopecia areata.
PentoxifyllineDrug
Topical treatment modality for alopecia areata.
MetforminDrug
Topical treatment modality for alopecia areata.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of hair regrowth in alopecia areata using SALT score.Time frame: 8 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Assiut university
Asyut, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.